NYSE:LLYEli Lilly And Co Stock Price, Forecast & News

$141.88

+0.27 (+0.19 %)

(As of 04/8/2020 08:27 AM ET)

Add

Compare

Today's Range

$140.05

Now: $141.88▼

$144.80

50-Day Range

$119.05

MA: $135.40▼

$143.20

52-Week Range

$101.36

Now: $141.88▼

$147.87

Volume3.81 million shs

Average Volume4.77 million shs

Market Capitalization$135.78 billion

P/E Ratio16.20

Dividend Yield2.09%

Beta0.16

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as migraine prevention. In addition, it offers immunology products for the treatment of rheumatoid arthritis and plaque psoriasis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia, and acute coronary syndrome. Further, the company provides animal health products, such as cattle feed additives; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and enteric diseases in swine and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; Nektar Therapeutics; NextCure, Inc.; Dicerna Pharmaceuticals; AC Immune SA; and Avidity Biosciences, Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Beat the Market (BTM) Rank^™

2.5 Analyst's Opinion

Consensus Rating
Eli Lilly And Co has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $143.11, Eli Lilly And Co has a potential upside of 0.9% from its current price of $141.88.
Amount of Analyst Coverage
Eli Lilly And Co has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Eli Lilly And Co has received 1,000 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Eli Lilly And Co has received 823 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Eli Lilly And Co has received 54.85% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote “Outperform” if you believe LLY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.

4.2 Dividend Strength

Dividend Leadership
Eli Lilly And Co is a leading dividend payer. It pays a dividend yield of 2.09%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Eli Lilly And Co has been increasing its dividend for 5 years.
Dividend Coverage
The dividend payout ratio of Eli Lilly And Co is 49.01 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Eli Lilly And Co will have a dividend payout ratio of 37.28 % next year. This indicates that Eli Lilly And Co will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eli Lilly And Co insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $148,012,771.00 in company stock.
Percentage Held by Insiders
Only 0.09% of the stock of Eli Lilly And Co is held by insiders.
Percentage Held by Institutions
77.83% of the stock of Eli Lilly And Co is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Eli Lilly And Co are expected to grow by 17.28% in the coming year, from $6.77 to $7.94 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eli Lilly And Co is 16.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 12.02.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eli Lilly And Co is 16.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.40.
Price to Earnings Growth Ratio
Eli Lilly And Co has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Eli Lilly And Co has a P/B Ratio of 50.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.32 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:LLY

Previous Symbol

CUSIP53245710

CIK59478

Webhttp://www.lilly.com/

Phone317-276-2000

Debt

Debt-to-Equity Ratio5.30

Current Ratio1.16

Quick Ratio0.89

Price-To-Earnings

Trailing P/E Ratio16.20

Forward P/E Ratio20.96

P/E Growth1.74

Sales & Book Value

Annual Sales$22.32 billion

Price / Sales6.08

Cash Flow$7.19 per share

Price / Cash Flow19.72

Book Value$2.81 per share

Price / Book50.49

Profitability

EPS (Most Recent Fiscal Year)$6.04

Net Income$8.32 billion

Net Margins37.27%

Return on Equity192.27%

Return on Assets14.48%

Miscellaneous

Employees33,625

Outstanding Shares957,038,000

Market Cap$135.78 billion

Next Earnings Date4/23/2020 (Confirmed)

OptionableOptionable

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions

How has Eli Lilly And Co's stock been impacted by COVID-19 (Coronavirus)?

Eli Lilly And Co's stock was trading at $140.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LLY stock has increased by 1.3% and is now trading at $141.88. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eli Lilly And Co?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 2 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eli Lilly And Co.

When is Eli Lilly And Co's next earnings date?

Eli Lilly And Co is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for Eli Lilly And Co.

How can I listen to Eli Lilly And Co's earnings call?

Eli Lilly And Co will be holding an earnings conference call on Thursday, April 23rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Eli Lilly And Co's earnings last quarter?

Eli Lilly And Co (NYSE:LLY) released its quarterly earnings results on Thursday, January, 30th. The company reported $1.73 EPS for the quarter, topping the consensus estimate of $1.52 by $0.21. The business earned $6.11 billion during the quarter, compared to analyst estimates of $5.92 billion. Eli Lilly And Co had a net margin of 37.27% and a return on equity of 192.27%. The business's quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.33 earnings per share. View Eli Lilly And Co's earnings history.

How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?

Eli Lilly And Co declared a quarterly dividend on Monday, December 16th. Stockholders of record on Friday, February 14th will be given a dividend of $0.74 per share on Tuesday, March 10th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.09%. The ex-dividend date is Thursday, February 13th. This is an increase from Eli Lilly And Co's previous quarterly dividend of $0.65. View Eli Lilly And Co's dividend history.

What guidance has Eli Lilly And Co issued on next quarter's earnings?

Eli Lilly And Co updated its FY20 earnings guidance on Thursday, January, 30th. The company provided EPS guidance of $6.70-6.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.76. The company issued revenue guidance of $23.7-24.2 billion, compared to the consensus revenue estimate of $23.78 billion.

What price target have analysts set for LLY?

12 brokerages have issued 1-year price objectives for Eli Lilly And Co's stock. Their forecasts range from $117.49 to $168.00. On average, they anticipate Eli Lilly And Co's stock price to reach $143.11 in the next twelve months. This suggests a possible upside of 0.9% from the stock's current price. View analysts' price targets for Eli Lilly And Co.

What are Wall Street analysts saying about Eli Lilly And Co stock?

Here are some recent quotes from research analysts about Eli Lilly And Co stock:

1. According to Zacks Investment Research, "Lilly beat estimates for earnings in the first quarter. However, Lilly lowered its sales guidance for 2019. Revenue growth in 2019 is expected to be driven by higher demand for its newer drugs including Trulicity, Jardiance, Taltz, Verzenio and new migraine drug, Emgality as some older drugs like Cialis face generic competition. Lilly has made significant pipeline progress in the past year with several positive late-stage data readouts, multiple approvals and regulatory submissions. Lilly also added promising new pipeline assets through business development deals. The stock has outperformed the industry in the past year. However, competitive pressure on Lilly’s drugs is expected to rise in 2019. Generic competition for several drugs including Cialis, rising pricing pressure, currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line." (5/21/2019)
2. Cantor Fitzgerald analysts commented, ". EPS beat, we maintain our OW rating and 12- month PT of $143. We expect upward earnings revisions to move LLY’s shares higher. This should be driven by sales growth, margin expansion, and pipeline advancements." (4/30/2019)

Has Eli Lilly And Co been receiving favorable news coverage?

News headlines about LLY stock have trended very negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eli Lilly And Co earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutEli Lilly And Co.

Are investors shorting Eli Lilly And Co?

Eli Lilly And Co saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 10,890,000 shares, a drop of 11.1% from the February 13th total of 12,250,000 shares. Based on an average daily volume of 3,940,000 shares, the days-to-cover ratio is presently 2.8 days. Approximately 1.3% of the company's stock are short sold. View Eli Lilly And Co's Current Options Chain.

Who are some of Eli Lilly And Co's key competitors?

Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Pacira Biosciences (PCRX) and Zogenix (ZGNX).

What other stocks do shareholders of Eli Lilly And Co own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly And Co investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AT&T (T), Merck & Co., Inc. (MRK), Intel (INTC), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ) and Walt Disney (DIS).

Who are Eli Lilly And Co's key executives?

Eli Lilly And Co's management team includes the following people:

Mr. David A. Ricks, Chairman, CEO & Pres (Age 51)
Mr. Joshua L. Smiley, Sr. VP & CFO (Age 49)
Dr. Daniel M. Skovronsky, Sr. VP & Chief Scientific Officer (Age 45)
Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 56)
Mr. Jeffrey N. Simmons, Sr. VP & Pres of Elanco Animal Health (Age 52)

What is Eli Lilly And Co's stock symbol?

Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly And Co's major shareholders?

Eli Lilly And Co's stock is owned by a number of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.02%), Verde Servicos Internacionais S.A. (0.01%), Gradient Investments LLC (0.01%), First American Bank (0.01%), Centre Asset Management LLC (0.01%) and Park National Corp OH (0.00%). Company insiders that own Eli Lilly And Co stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, Christi Shaw, Daniel Skovronsky, David A Ricks, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill, Stephen F Fry and Susan Mahony. View institutional ownership trends for Eli Lilly And Co.

Which major investors are selling Eli Lilly And Co stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Centre Asset Management LLC, Gradient Investments LLC, Cullinan Associates Inc., Park National Corp OH, Pensionfund DSM Netherlands, First National Bank of Mount Dora Trust Investment Services, Private Trust Co. NA, and Triangle Securities Wealth Management. Company insiders that have sold Eli Lilly And Co company stock in the last year include Alfonso G Zulueta, Christi Shaw, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill, and Stephen F Fry. View insider buying and selling activity for Eli Lilly And Co.

Which major investors are buying Eli Lilly And Co stock?

LLY stock was acquired by a variety of institutional investors in the last quarter, including Verde Servicos Internacionais S.A., State of Alaska Department of Revenue, IBM Retirement Fund, American National Bank, Global Trust Asset Management LLC, Hotaling Investment Management LLC, IMS Capital Management, and Fulton Bank N.A.. Company insiders that have bought Eli Lilly And Co stock in the last two years include Anne E White, Daniel Skovronsky, David A Ricks, Jackson P Tai, and Joshua L Smiley. View insider buying and selling activity for Eli Lilly And Co.

How do I buy shares of Eli Lilly And Co?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eli Lilly And Co's stock price today?

One share of LLY stock can currently be purchased for approximately $141.88.

How big of a company is Eli Lilly And Co?

Eli Lilly And Co has a market capitalization of $135.78 billion and generates $22.32 billion in revenue each year. The company earns $8.32 billion in net income (profit) each year or $6.04 on an earnings per share basis. Eli Lilly And Co employs 33,625 workers across the globe. View additional information about Eli Lilly And Co.

What is Eli Lilly And Co's official website?

The official website for Eli Lilly And Co is http://www.lilly.com/.

How can I contact Eli Lilly And Co?

Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Featured Article: Trading Strategy Methods for Individual Investors

NYSE:LLYEli Lilly And Co Stock Price, Forecast & News

Adding

Adding

Adding Eli Lilly And Co

Beat the Market (BTM) Rank™

2.5 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage

2.7 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment